Position in SCYX
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$570,521
+$539,198 QoQ
Shares Held
622,161
+2303.4% QoQ
Ownership
0.783%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#10
of 44 holders
Holding Since
Jun 2021
8 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in SCYX Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026MILLENNIUM MANAGEMENT LLC holds $1,131,904,343 across 44 Drug Manufacturers - Specialty & Generic names. SCYX ranks #38 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ZTS |
Zoetis Inc.
|
1,649,955 | $195,041,180 | |
| 2 | SUPN |
Supernus Pharmaceuticals, Inc.
|
3,315,973 | $171,402,644 | |
| 3 | NBIX |
Neurocrine Biosciences Inc
|
1,247,447 | $164,338,667 | |
| 4 | INDV |
Indivior Pharmaceuticals, Inc.
|
4,595,535 | $140,071,906 | |
| 5 | UTHR |
UNITED THERAPEUTICS Corp
|
153,372 | $90,946,528 | |
| 6 | TEVA |
Teva Pharmaceutical Industries Ltd
|
1,893,845 | $57,042,611 | |
| 7 | PRGO |
PERRIGO Co plc
|
4,279,731 | $45,964,310 | |
| 8 | ANIP |
Ani Pharmaceuticals Inc
|
592,013 | $45,525,799 |
All Filings in SCYX
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $570,521 | 622,161 | Shares | Sole | 2026-05-15 | |
| 2024-12-31 | $31,323 | 25,887 | Shares | Sole | 2025-02-14 | |
| 2024-03-31 | $61,337 | 41,726 | Shares | Sole | 2024-05-15 | |
| 2023-12-31 | $115,322 | 51,714 | Shares | Sole | 2024-02-14 | |
| 2023-09-30 | $212,949 | 93,399 | Shares | Sole | 2023-11-14 | |
| 2023-06-30 | $275,819 | 93,498 | Shares | Sole | 2023-08-14 | |
| 2022-03-31 | $176,258 | 45,079 | Shares | Sole | 2022-05-16 | |
| 2021-06-30 | $186,737 | 25,372 | Shares | Sole | 2021-08-16 | |
| No filing history on record for this holder in this stock. | ||||||